Sarah Cannon Research Institute (SCRI) has announced a partnership with AstraZeneca to progress technological integration and operational efficiency in the delivery of oncology clinical trials.
The collaboration will see the implementation of solutions to expedite timelines for clinical trial delivery, alleviate the administrative burden on sites, and refine patient enrolment processes.
Go deeper with GlobalData
Furthermore, the alliance will focus on boosting participant enrolment in the US.
As per the deal, the electronic health record (EHR) data will be integrated with electronic data capture (EDC) systems through the EHR2EDC (E2E) technology developed by precision medicine platform Genospace and SCRI Development Innovations.
SCRI CEO Dee Anna Smith said: “Improving end-to-end research operations will have a great impact on the industry’s ability to increase the pace of drug development without compromising quality.
See Also:
“Our collaboration with AstraZeneca has the potential to accelerate our mutual efforts to bring novel therapies to more people with cancer, through more physicians, across even more communities.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThis technological advancement has shown promising results by reducing the time required for site-based data entry, cutting down manual labour and monitoring expenses.
Moreover, this approach enhances the quality of the data and expedites clinical trial decision-making.
The E2E system and SCRI’s new model aim to synchronise end-to-end clinical research management, linking over 1,300 physicians and providing access to trials for a diverse array of tumour types at more than 250 locations in 24 US states.
AstraZeneca Oncology R&D Clinical Operations vice-president Michele Sample said: “Our ongoing commitment to personalised and effective medical interventions to people living with cancer means we are continually innovating to improve accessibility to trial participation and meet the current and future needs of clinical trial execution.
“Working with SCRI to enhance US enrolment and streamline clinical trial data collection is a tremendous opportunity to increase the diversity of clinical trial participants in the US and accelerate clinical trial delivery timelines.”
